of exposure to active and passive tobacco smoke on urinary eicosanoids in relevant asthma populations.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Neil C. Thomson, M.D.*
University of Glasgow
Glasgow, United Kingdom

*Corresponding author (e-mail: neil.thomson@glasgow.ac.uk).

References

1. Kolmert J, Gómez C, Balgoma D, Sjödin M, Bood J, Konradsen JR, et al.; U-BIOPRED Study Group, on behalf of the U-BIOPRED Study Group. Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation: a clinical observational study. Am J Respir Crit Care Med 2021;203:37–53.

2. Thomson NC, Chaudhuri R, Spears M, Messow CM, Jelinsky S, Miele G, et al. Arachidonic acid metabolites and enzyme transcripts in asthma are altered by cigarette smoking. Allergy 2014;69:527–536.

3. FAuler J, Frölich JC. Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 1997;27:43–47.

4. Gaki E, Papatheodorou G, Ischaki E, Grammenou V, Papa I, Loukides S. Leukotriene E4 (L TE4) in urine in patients with asthma and COPD—the effect of smoking habit. Respir Med 2007;101:826–832.

5. Rabinovitch N, Reisdorph N, Silveira L, Gelfand EW. Urinary leukotriene E4 levels identify children with tobacco smoke exposure at risk for asthma exacerbation. J Allergy Clin Immunol 2011;128:323–327.

6. Konno S, Taniguchi N, Makita H, Nakamaru Y, Shimizu K, Shijubo N, et al.; HiCARAT Investigators. Distinct phenotypes of smokers with asthma using this dual inclusion criteria for the smokers. Ann Am Thorac Soc 2018;15:33–41.

Copyright © 2021 by the American Thoracic Society

Reply to Thomson

From the Authors:

We thank Dr. Thomson for raising the important issue of the effects of smoking status upon observed urinary eicosanoid metabolite levels. In our recent publication reporting the utility of certain urinary eicosanoids in identifying type 2 (T2) inflammation in the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes) study (1), we examined the effects of a number of potential confounders; however, we did not report on the influence of current smoking. To mimic real-life conditions, the U-BIOPRED study indeed recruited one group of individuals (n = 109) that included past (>5 pack-years) and current smokers. As reported in Table 3 of our paper, the majority of the measured eicosanoid metabolites exhibited no significant differences between the smoking and nonsmoking (n = 302) group of participants with severe asthma using this dual inclusion criteria for the smokers. Although there were small differences in the 2,3-dinor thromboxane B2 metabolite and the isoprostane 8-iso-prostaglandin (PG)F2α, the most pronounced difference related to the main metabolite of prostaglandin E2 (PGE2), which was higher in both men and women in the smoking group, in line with published data (2). In contrast, the T2-associated metabolites of cysteinyl leukotrienes and PGD2 were the same in the smoking and nonsmoking patients with severe asthma.

In response to Dr. Thomson’s inquiry, we have now extracted data for the subgroup of current smokers (n = 42) and compared the T2-associated urinary eicosanoids in question with those in the larger group of nonsmoking patients with severe asthma (Table 1). Neither leukotriene E4 (LTE4) excretion nor recovery of the two main PGD2 metabolites, 2,3-dinor-11β-PGF2α, and tetranor-PGDMD, were significantly different between the current smokers and the larger group of nonsmokers. Interestingly, in the same subgroup analysis, fractional exhaled nitric oxide was 41% lower in current smokers (P < 0.001), validating that one established effect of smoking (3) was replicated in the U-BIOPRED study. In terms of other T2 markers, serum peristin was slightly (14%) lower in the smokers (P = 0.013), whereas blood eosinophil counts were the same in both groups (P = 0.482).

With respect to passive smoking, urinary cotinine was in fact measured in spot samples of 509 of the participants with asthma but was only found present in 33 of the those with severe asthma belonging to the smokers/ex-smokers group. This unfortunately does not permit analysis of a potential influence of passive smoking because cotinine-positive cases most likely reflect active smoking at the time of the study visit.

Dr. Thomson also raised the question concerning the possible confounding effect of smoking status upon our data supporting the ability of urinary PGD2 and LTE4 to identify T2 asthma. To further examine this important point, we performed a focused analysis of the reported extreme groups in Figure 6 of our paper. Based upon quartile concentration-based quartiles of the two main PGD2 metabolites (c-PGD2) and LTE4, the groups contained less than 12% and 7% current smokers in the 75th quartile for c-PGD2 and LTE4, respectively. In those subgroups of participants, their quartile median values did not contribute to any different extent to the total 75th quartile median. Consequently, the contribution from current smoking participants to define concentration-based quartiles of urinary concentration of c-PGD2 and LTE4 could not be considered to be confounded by current smokers.

In summary, the herein reported new analysis of data for the current smoking group of U-BIOPRED participants does not lend support to the concept that smoking may induce high levels of urinary LTE4 or metabolites of PGD2. However, because only 42 subjects were current smokers, we believe that the data should be interpreted with caution. Clearly, as referred to in Dr. Thomson’s letter, there are reports that suggest such effects, in particular his own work (4). The latter study is well designed and conducted; however, at that time T2 markers in blood were not assessed, so it is difficult to directly compare the findings with ours. In addition, earlier work has reported an increase in urinary LTE4 in children with asthma exposed to environmental tobacco smoke assessed by urinary cotinine levels...
There are subsequently indications in the literature of an interaction between both active and passive smoking with urinary eicosanoid levels. We believe future studies specifically designed to address active and passive smoking influences on not only T2 markers but also the whole panel of urinary eicosanoids are warranted. We thank Dr. Thompson for this opportunity to reanalyze part of our own data and agree very much that all proposed biomarkers should be rigorously tested for confounding factors.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Johan Kolmert, Ph.D.
Sven-Erik Dahlén, M.D., Ph.D.
Craig E. Wheelock, Ph.D.
Karolinska Institutet
Stockholm, Sweden

On behalf of all the authors

ORCID ID: 0000-0002-8113-0653 (C.E.W.).

*Corresponding author (e-mail: craig.wheelock@ki.se).

Table 1. Urinary Concentration of T2 Inflammation-associated Urinary Eicosanoids and Common T2 Inflammatory Markers in the U-BIOPRED Participants with Severe Asthma

|                                | Nonsmoker with Severe Asthma (n = 302) | Current Smoker with Severe Asthma (n = 42)* | P Value† |
|--------------------------------|----------------------------------------|---------------------------------------------|----------|
| 2,3-Dinor-11β-PGF₂α            | 58 (39–80)                             | 67 (48–86)                                  | 0.115    |
| Tetranor-PGDM                 | 268 (191–368)                          | 252 (198–364)                               | 0.696    |
| LTE₄                          | 6.3 (3.9–11.0)                         | 7.0 (4.5–12.7)                              | 0.571    |
| FENO, ppb                     | 27 (16–48) (n = 281)                   | 16 (10–32) (n = 41)                         | <0.001   |
| Blood eosinophils, counts/µl  | 200 (100–400) (n = 294)                | 210 (130–413) (n = 42)                      | 0.482    |
| Serum periostin, ng/ml        | 50 (42–60) (n = 250)                   | 43 (37–53) (n = 33)                         | 0.013    |

Definition of abbreviations: 2,3-Dinor-11β-PGF₂α = 2,3 dinor-11β-prostaglandin F₂α; FENO = fractional exhaled nitric oxide; LTE₄ = cysteinyl leukotriene E₄; T2 = type 2; TetranorPGDM = tetranor prostaglandin D₂ metabolite.

Values are presented as median (interquartile range). Urinary eicosanoids are expressed in ng/mmol creatinine.

*In the U-BIOPRED study, there were n = 109 current or ex-smokers. Of these individuals, n = 42 were defined as current smokers and are included in the current analysis.

†Statistical comparisons were performed with a Mann-Whitney test, and bold values indicate P < 0.05.

References

1. Kolmert J, Gómez C, Balgoma D, Sjödin M, Bood J, Konradsen JR, et al.; U-BIOPRED Study Group, on behalf of the U-BIOPRED Study Group. Urinary leukotriene E₄ and prostaglandin D₂ metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation: a clinical observational study. Am J Respir Crit Care Med 2021;203:37–53.

2. Gross ND, Boyle JO, Morrow JD, Williams MK, Moskowitz CS, Subbaramaiah K, et al. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E₂, are increased in smokers. Clin Cancer Res 2005;11:6087–6093.

3. Thomson NC, Chaudhuri R, Heaney LG, Bucknall C, Niven RM, Brightling CE, et al. Clinical outcomes and inflammatory biomarkers in current smokers and ex-smokers with severe asthma. J Allergy Clin Immunol 2013;131:1008–1016.

4. Thomson NC, Chaudhuri R, Spears M, Messow CM, Jelinsky S, Miele G, et al. Arachidonic acid metabolites and enzyme transcripts in asthma are altered by cigarette smoking. Allergy 2014;69:527–536.

5. Rabinovitch N, Reisdorph N, Silveira L, Gelfand EW. Urinary leukotriene E₄ levels identify children with tobacco smoke exposure at risk for asthma exacerbation. J Allergy Clin Immunol 2011;128:323–327.